Immix Biopharma, Inc. IMMX

IMMX Company Overview

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies and precision oncology therapeutics, with a primary emphasis on hematologic malignancies and solid tumors. The company operates within the biotechnology and immuno-oncology industries and has centered much of its development strategy on chimeric antigen receptor T-cell (CAR-T) therapies through its subsidiary Nexcella, Inc. Its pipeline includes investigational therapies targeting difficult-to-treat cancers, including multiple myeloma and light-chain amyloidosis. Revenue generation has historically been limited because the company remains in the clinical development stage and has not reported commercialized products as a primary revenue source in public filings.

Immix Biopharma was founded in 2012 and evolved from an early-stage oncology therapeutics company into a broader immunotherapy-focused biotechnology platform. Public disclosures, including SEC filings, indicate that the company expanded its strategic focus through acquisitions and licensing arrangements tied to CAR-T development. The company’s positioning is tied to developing therapies intended to improve efficacy, safety, and manufacturing scalability in oncology treatment, particularly in indications where existing therapies face relapse or tolerability limitations.